In every gram of bone marrow, in every fragment of adipose tissue, resides a discrete but remarkable cell population. Mesenchymal stem cells (MSCs) possess a rare capacity: differentiating into bone, cartilage and fat, and above all orchestrating tissue repair without transforming themselves. This functional duality makes them one of the most studied tools in regenerative medicine. And one of the most misunderstood by the general public.
Between rigorous clinical trials and offshore clinics selling "rejuvenating stem cell" injections, the gap is considerable. The distance between what science has demonstrated and what the market promises warrants careful examination.
Definition and Tissue Origins: One Cell, Multiple Sources
The term "mesenchymal stem cell" was popularized by Arnold Caplan in the 1990s to designate multipotent stromal cells (support cells capable of transforming into several tissue types) initially isolated from bone marrow (PubMed). Since then, the International Society for Cellular Therapy (ISCT) proposed minimal defining criteria in 2006: plastic adherence in culture, expression of specific surface markers (the proteins CD73, CD90, CD105, which serve as cellular identity cards) with absence of hematopoietic markers (CD45, CD34, CD14), and trilineage differentiation capacity: the ability to transform into bone cells (osteoblasts), cartilage cells (chondrocytes) and fat cells (adipocytes) in the laboratory (PubMed).
These criteria appear simple. They mask a more complex reality. MSCs are not a homogeneous population. Their phenotype, differentiation potential and secretory activity vary considerably depending on their tissue of origin.
Bone marrow remains the historical and best-characterized source. MSCs represent a tiny fraction there (0.001 to 0.01% of nucleated cells), but they expand efficiently in culture. Adipose tissue provides an abundant and easily accessible alternative via liposuction. Adipose-derived MSCs (AD-MSCs) are more numerous per gram of tissue and display a distinct secretory profile, with more pronounced angiogenic activity (the ability to stimulate new blood vessel formation). The umbilical cord (Wharton's jelly) yields more primitive MSCs, with superior proliferative potential and reduced immunogenicity. Dental pulp, finally, harbors MSCs with strong neurotrophic capacity (supporting and protecting nerve cells).
This diversity is not anecdotal. It explains why clinical outcomes vary depending on the cell source used.
The Secretome: The True Weapon of MSCs
For two decades, the dominant paradigm assumed that MSCs acted by directly differentiating into the injured tissue. An MSC injected into osteoarthritic cartilage would become a chondrocyte. An MSC implanted into an infarct would become a cardiomyocyte. This hypothesis proved largely incorrect.
Cell-tracing studies showed that transplanted MSCs rarely survive beyond a few days in the host tissue. Their long-term engraftment rate is below 1% in most animal models. Yet therapeutic effects persist well beyond the survival of injected cells (PubMed).
The answer lies in the secretome, the full set of molecules that MSCs secrete into their environment. MSCs release a complex cocktail of bioactive molecules that modify the local tissue environment:
Exosomes (extracellular vesicles of 30 to 150 nm) transport microRNAs, proteins and bioactive lipids capable of reprogramming recipient cells. Growth factors (VEGF, HGF, IGF-1, FGF-2) stimulate angiogenesis and cell proliferation. Anti-inflammatory cytokines (IL-10, TGF-β) and prostaglandin E2 (PGE2) modulate the local immune response. STC-1 (stanniocalcin-1) protects mitochondria from oxidative stress.
This represents a major conceptual shift. MSCs are not building blocks. They are living pharmacies.
Transplanted MSCs rarely survive more than a few days in host tissue. Their therapeutic effect relies on their paracrine secretome, not direct differentiation.
Immunomodulation: Reprogramming the Immune Response
One of the best-documented properties of MSCs is their ability to modulate the immune system. This immunomodulation is bidirectional and context-dependent.
In the presence of pro-inflammatory cytokines (IFN-γ, TNF-α), MSCs activate and acquire a potent immunosuppressive phenotype. They inhibit the proliferation of T lymphocytes (immune cells that orchestrate the adaptive response) through secretion of indoleamine 2,3-dioxygenase (IDO), an enzyme that degrades tryptophan and deprives T cells of an amino acid essential for their multiplication. They promote the expansion of regulatory T cells (Treg), the cells that moderate excessive immune responses. They redirect macrophages (sentinel cells of the immune system) from a pro-inflammatory profile (called M1) toward an anti-inflammatory and reparative profile (called M2) (PubMed).
This property explains the interest in MSCs for autoimmune diseases and excessive immune reactions. In the absence of inflammatory signals, MSCs remain relatively inert immunologically. They do not constitutively suppress the immune system. They respond to local inflammation.
This contextual reactivity is both an advantage (no generalized immunosuppression) and a challenge (results depend on the recipient's inflammatory state at the time of injection).
Clinical Applications: Where the Science Stands
Osteoarthritis
Osteoarthritis is the most studied indication for intra-articular MSC therapies. A 2019 meta-analysis covering 18 clinical trials showed significant improvement in pain and joint function scores at 12 months, with evidence of structural cartilage effects in some studies (cartilage thickness measured by MRI) (PubMed). However, protocol heterogeneity (cell source, cell number, injection frequency) makes comparisons difficult. No MSC product is FDA-approved for osteoarthritis.
Graft-Versus-Host Disease (GVHD)
GVHD remains the most advanced indication from a regulatory standpoint. In Japan, Temcell (allogeneic bone marrow MSCs) received conditional approval for corticosteroid-resistant acute GVHD. In Europe, Alofisel (darvadstrocel), based on adipose-derived MSCs, was approved by the EMA in 2018 for complex perianal fistulas in Crohn's disease — the first MSC therapy approved in Europe (PubMed).
Cardiac Injury
Clinical trials for myocardial infarction show modest but measurable results. The POSEIDON trial compared autologous and allogeneic MSCs in heart failure patients. Both approaches improved left ventricular function, exercise capacity and quality of life at 12 months, with an acceptable safety profile (PubMed). The magnitude of effect remains modest. MSCs do not regenerate lost cardiac muscle. They attenuate fibrotic remodeling and stimulate local angiogenesis.
MSCs and Aging: A Programmed Decline
The MSC pool does not remain constant throughout life. Their number, proliferative capacity and differentiation potential decline with age. MSCs from elderly donors show shorter telomeres, reduced mitochondrial activity, increased oxidative stress and a modified secretory profile — fewer trophic factors, more pro-inflammatory cytokines.
This phenomenon is directly linked to cellular senescence. Aged MSCs express elevated levels of p16INK4a and p21, proteins that block cell division and characterize senescent cells in other tissues. They acquire a SASP (Senescence-Associated Secretory Phenotype), an inflammatory secretion profile typical of aging cells, that compromises not only their own function but that of the surrounding tissue niche (PubMed).
The consequences are concrete: slower wound healing, bone loss, diminished cartilage regenerative capacity, increased fibrosis. MSC compartment degradation is one of the mechanisms linking cellular aging to functional tissue decline.
This also poses a practical problem for autologous therapy: using an elderly patient's own MSCs means transplanting cells that are already compromised.
Autologous vs Allogeneic: The Central Debate
Autologous therapy (the patient's own MSCs) eliminates the risk of immune rejection. But it requires an invasive harvest (bone marrow aspiration, liposuction), a culture period of several weeks, and cell quality depends on the donor's age and health status.
Allogeneic therapy (MSCs from a young, healthy donor) offers a standardized, immediately available ("off the shelf") product with superior regenerative potential. MSCs are considered "immune-privileged" due to their low HLA class II expression (the surface markers the immune system uses to distinguish "self" from "foreign") and absence of co-stimulatory molecules. In practice, this immune privilege is relative. Studies have documented anti-HLA antibody formation after repeated allogeneic MSC injections, with potential reduction in efficacy during subsequent administrations.
The POSEIDON trial provided a direct comparison: allogeneic MSCs were as effective as autologous ones in heart failure, without clinically significant immune reactions. But the question of long-term immunogenicity after repeated doses remains open.
Commercial Clinics: What the Science Actually Says
Hundreds of clinics worldwide offer "stem cell" injections for rejuvenation, osteoarthritis, neurological diseases, erectile dysfunction and virtually every conceivable condition. Prices range from $5,000 to $50,000 per session.
In 2016, a systematic analysis identified 570 US clinics offering unapproved stem cell therapies. Most used adipose-derived MSCs prepared at the point of care (same day), without culture expansion or standardized cell characterization (PubMed). No evidence of efficacy was presented for the vast majority of these indications.
The FDA took action. In 2017, it obtained injunctions against clinics injecting unapproved adipose MSCs into eyes (documented cases of blindness), joints and intravenously. The regulatory position is clear: a manipulated MSC (cultured, differentiated, combined with a scaffold) is a biological product requiring market authorization.
Exosomes: Cell-Free Therapy
If MSCs act primarily through their secretome, why not use the secretome directly, without the cells? This is the rationale behind cell-free therapies based on exosomes.
MSC-derived exosomes reproduce a significant portion of the paracrine effects of parent MSCs. They cross the blood-brain barrier. They do not replicate (no tumorigenic risk). They can be lyophilized, stored and standardized. In preclinical models, MSC exosomes have shown protective effects in cerebral ischemia, myocardial infarction, hepatic fibrosis and wound healing.
The transition to human clinical use remains preliminary. The challenges are real: standardization of isolation methods, quantification of microRNA content, definition of effective doses, optimal administration routes. But the potential is considerable. A cell-free, standardized, storable product with no risk of rejection or transformation — that is the holy grail of regenerative medicine.
Risks, Limitations and Regulatory Framework
The risk of tumor formation remains the most discussed theoretical concern. MSCs in prolonged culture can acquire chromosomal abnormalities. In practice, clinical studies with long-term follow-up have not documented increased tumor risk in MSC-treated patients. But follow-up remains limited (rarely beyond 10 years).
Preparation heterogeneity is a concrete problem. Two batches of MSCs from the same donor, cultured under slightly different conditions, can have distinct functional profiles. The absence of standardized functional markers (beyond ISCT surface criteria) makes comparison between clinical trials hazardous.
The regulatory framework reflects this complexity. The FDA classifies manipulated MSCs as biological products (351 HCT/Ps) requiring a BLA (Biologics License Application). The EMA requires marketing authorization for Advanced Therapy Medicinal Products (ATMPs). As of 2026, only a handful of MSC products have received these approvals worldwide.
Perspectives: iPSC-MSCs and Cellular Engineering
The next frontier is generating MSCs from induced pluripotent stem cells (iPSC-MSCs): adult cells reprogrammed in the laboratory to regain a potential comparable to that of embryonic cells. This approach circumvents two major limitations: tissue availability and cellular aging. iPSC-MSCs can be produced in unlimited quantities from a single iPSC line, with a rejuvenated phenotype and superior functional potential compared to MSCs from elderly donors.
Genetic engineering opens further possibilities. MSCs modified to overexpress specific factors (VEGF, BMP-2, IL-10) could target specific pathologies with enhanced efficacy. MSC biobanking (cryopreservation of umbilical cord MSCs at birth) constitutes a biological insurance whose clinical value remains to be demonstrated, but whose scientific rationale is sound.
The MSC field illustrates a permanent tension in biomedicine: between real biological potential (considerable) and clinical translation (slow, complex, subject to justified regulatory requirements). Commercial shortcuts serve no one. Scientific rigor will eventually deliver therapies that transform regenerative medicine. It is a matter of time, not principle.
Frequently asked questions
References
- Caplan AI. Mesenchymal Stem Cells: Time to Change the Name! Stem Cells Transl Med. 2017;6(6):1445-1451 (PubMed).
- Dominici M et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8(4):315-317 (PubMed).
- Gnecchi M et al. Paracrine mechanisms of mesenchymal stem cells in tissue repair. Methods Mol Biol. 2016;1416:123-146 (PubMed).
- Uccelli A, Moretta L, Pistoia V. Mesenchymal stem cells in health and disease. Nat Rev Immunol. 2008;8(9):726-736 (PubMed).
- Matas J et al. Umbilical Cord-Derived Mesenchymal Stromal Cells (MSCs) for Knee Osteoarthritis: Repeated MSC Dosing Is Superior to a Single MSC Dose and to Hyaluronic Acid in a Controlled Randomized Phase I/II Trial. Stem Cells Transl Med. 2019;8(3):215-224 (PubMed).
- Panés J et al. Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial. Lancet. 2016;388(10051):1281-1290 (PubMed).
- Hare JM et al. Comparison of allogeneic vs autologous bone marrow-derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial. JAMA. 2012;308(22):2369-2379 (PubMed).
- Li Y et al. Senescence of mesenchymal stem cells. Int J Mol Med. 2017;39(4):775-782 (PubMed).
- Turner L, Knoepfler P. Selling Stem Cells in the USA: Assessing the Direct-to-Consumer Industry. Cell Stem Cell. 2016;19(2):154-157 (PubMed).
